The role of ranibizumab in the management of diabetic retinopathy

References

• Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102(4):527-32
   PubMed Web of Science ®Google Scholar
• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35(3):556-64
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group Ophthalmol 1991;98(5 Suppl):786-806
   PubMed Web of Science ®Google Scholar
• Narayan KM, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006;29(9):2114-16
   PubMed Web of Science ®Google Scholar
• Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. Jama 2010;304(6):649-56
   PubMed Web of Science ®Google Scholar
• CDC. National Diabetes Statistics Report, 2014. Available from: www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf [Last accessed online January 2015]
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44(8):968-83
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352(9131):854-65
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363(3):233-44
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Study Research Group. Photocoagulation Treatment of Proliferative Diabetic Retinopathy: Clinical Application of Diabetic Retinopathy Study (DRS) Findings, DRS Report Number 8. Ophthalmol 1981;88(7):583-600
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmol 1978;85(1):82-106
   PubMed Web of Science ®Google Scholar
• Group ETDRS. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103(12):1796-806
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest 1995;72(6):615-18
   PubMed Web of Science ®Google Scholar
• Adamis AP, Aiello LP, D’Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis 1999;3(1):9-14
   PubMedGoogle Scholar
• Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina (Philadelphia, Pa.) 2005;25(2):111-18
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142(6):961-9
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmol 2009;116(11):2175-81; e2171
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmol 2010;117(6):1064-77; e1035
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmol 2011;118(4):615-25
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA approves Lucentis to treat diabetic macular edema. 2012. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315130.htm [Last accessed online, January 2015]
   Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmol 2012;119(4):789-801
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012;130(9):1145-52
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmol 2015;122(2):367-74
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331(22):1480-7
   PubMed Web of Science ®Google Scholar
• Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118(4):445-50
   PubMed Web of Science ®Google Scholar
• Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145(3):574-84
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Van Anden E, et al. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004;45(2):617-24
   PubMed Web of Science ®Google Scholar
• Aiello L, Northrup JM, Keyt BA, et al. HYpoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113(12):1538-44
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult Primate. Ophthalmology 1996;103(11):1820-8
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77; e1035
   PubMed Web of Science ®Google Scholar
• Muller YA, Chen Y, Christinger HW, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure (London, England : 1993) 1998;6(9):1153-67
   PubMed Web of Science ®Google Scholar
• Baca M, Presta LG, O’Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem 1997;272(16):10678-84
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27(5):536-44
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa.) 2006;26(8):859-70
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao Z, Kaila N, et al. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology 2014;121(11):2237-46
   PubMed Web of Science ®Google Scholar
• Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293(4):865-81
   PubMed Web of Science ®Google Scholar
• Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85(4):425-30
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 2013;54(3):1616-24
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 2011;408(2):276-81
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15(2):171-85
   PubMed Web of Science ®Google Scholar
• Yang J, Wang X, Fuh G, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm 2014;11(10):3421-30
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120(10):2013-22
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema: The RESTORE Extension Study. Ophthalmology 2014;121(5):1045-53
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117(11):2146-51
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131(2):139-45
   PubMed Web of Science ®Google Scholar
• Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119(11):2312-18
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122(2):375-81
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372(13):1193-203
   PubMed Web of Science ®Google Scholar
• Agarwal A, Soliman MK, Sepah YJ, et al. Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmacogenomics and personalized medicine 2014;7:399-409
   PubMedGoogle Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. ETDRS Report number 10. Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. Ophthalmology 1991;98(5 Suppl):786-806
   PubMed Web of Science ®Google Scholar
• Vander JF, Duker JS, Benson WE, et al. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991;98(10):1575-9
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015;122(2):367-74
   Google Scholar
• Bressler SB, Qin H, Melia M, et al. Exploratory analysis of effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013;131(8):1033-40
   Google Scholar
• Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110(12):2386-94
   PubMed Web of Science ®Google Scholar
• McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina (Philadelphia, Pa.) 1985;5(1):5-10
   PubMed Web of Science ®Google Scholar
• Higgins KE, Meyers SM, Jaffe MJ, et al. Temporary loss of foveal contrast sensitivity associated with panretinal photocoagulation. Arch Ophthalmol 1986;104(7):997-1003
   PubMed Web of Science ®Google Scholar
• Ferraz DA, Vasquez LM, Preti RC, et al. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina (Philadelphia, Pa.) 2014;35(2):280-7
   Web of Science ®Google Scholar
• Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol (Copenh) 2011;89(7):e567-72
   Web of Science ®Google Scholar
• Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina (Philadelphia, Pa.) 2011;31(6):1009-27
   PubMed Web of Science ®Google Scholar
• Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: Two-year results of a randomized trial diabetic retinopathy vitrectomy study report 2 the diabetic retinopathy vitrectomy study research group. Arch Ophthalmol 1985;103(11):1644-52
   PubMed Web of Science ®Google Scholar
• Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina (Philadelphia, Pa.) 2006;26(3):275-8
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Torres K, Glassman AR, et al. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA ophthalmology 2014;132(7):889-90
   Google Scholar
• Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014;121(9):1783-9
   PubMed Web of Science ®Google Scholar
• Pershing S, Enns EA, Matesic B, et al. Cost-Effectiveness of Treatment of Diabetic Macular Edema. Ann Intern Med 2014;160(1):18-29
   PubMed Web of Science ®Google Scholar
• Lucentis Price Guide. Available from: www.drugs.com/price-guide/lucentis [Last accessed online January 25, 2015]
   Google Scholar
• Eylea Price Guide. Available from: www.drugs.com/price-guide/eylea [Last accessed online January 25, 2015]
   Google Scholar
• Hutton D, Newman-Casey PA, Tavag M, et al. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff (Millwood) 2014;33(6):931-9
   PubMed Web of Science ®Google Scholar
• Stein JD, Newman-Casey PA, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121(4):936-45
   PubMed Web of Science ®Google Scholar
• Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group Arch Ophthalmol 1995;113(9):1144-55
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG. Treatment choice for diabetic macular edema. N Engl J Med 2015;372(13):1260-1
   PubMed Web of Science ®Google Scholar
• Phillips WB2nd, Tasman WS. Postoperative endophthalmitis in association with diabetes mellitus. Ophthalmology 1994;101(3):508-18
   PubMed Web of Science ®Google Scholar
• Coburn PS, Wiskur BJ, Christy E, Callegan MC. The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis. Invest Ophthalmol Vis Sci 2012;53(12):7426-31
   PubMed Web of Science ®Google Scholar
• FDA News Release. 2015.FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm433392.htm [Last accessed online, March 27, 2015]
   Google Scholar
• A study to evaluate asp8232 in reducing central retinal thickness in subjects with diabetic macular edema (DME) (VIDI). Available from: https://clinicaltrials.gov/ct2/show/NCT02302079
   Google Scholar
• A Phase 1, open-label study of teprotumumab in patients with diabetic macular edema (DME). Available from: https://clinicaltrials.gov/ct2/show/NCT02103283
   Google Scholar
• Ranibizumab for edema of the macula in diabetes: protocol 3 with high dose - the READ 3 study. Available from: https://clinicaltrials.gov/ct2/show/NCT01077401
   Google Scholar
• A Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema. Available from: https://clinicaltrials.gov/ct2/show/NCT01994291
   Google Scholar
• Efficacy and safety trial of intravitreal injections combined with PRP for the treatment of CSME secondary to diabetes mellitus (DAVE). Available from: https://clinicaltrials.gov/ct2/show/NCT01552408
   Google Scholar
• Microperimetry and optical coherence tomography (OCT) with lucentis for diabetic macular edema (DME) (MORE). Available from: https://clinicaltrials.gov/ct2/show/NCT00885794
   Google Scholar
• Efficacy and safety of lucentis® use in patients with diabetic macular edema evaluating a spaced out follow-up after intensive treatment phase (CONSTELLATION). Available from: https://clinicaltrials.gov/ct2/show/NCT02032173
   Google Scholar
• Phase II combination steroid and anti-VEGF for persistent DME. Available from: https://clinicaltrials.gov/ct2/show/NCT01945866
   Google Scholar
• Bevacizumab versus ranibizumab for the treatment of diabetic macular edema (IBERA-DME). Available from: https://clinicaltrials.gov/ct2/show/NCT01487629
   Google Scholar
• Prompt panretinal photocoagulation versus ranibizumab+deferred panretinal photocoagulation for proliferative diabetic retinopathy (Protocol S). Available from: https://clinicaltrials.gov/ct2/show/NCT01489189
   Google Scholar
• Prospective, Randomized, Multicentre, Open-label, Phase II/ III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS). Available from: https://clinicaltrials.gov/ct2/show/NCT01941329
   Google Scholar
• Safety and efficacy of intravitreal ranibizumab as a preoperative adjunct treatment before vitrectomy surgery in proliferative diabetic retinopathy (PDR) compared to vitrectomy alone (VITARM). Available from: https://clinicaltrials.gov/ct2/show/NCT00931125
   Google Scholar
• Intravitreal ranibizumab for persistent new vessels in diabetic retinopathy(Inipe Study) (INIPE). Available from: https://clinicaltrials.gov/ct2/show/NCT00993525
   Google Scholar
• Multicenter 12 months clinical study to evaluate efficacy and safety of ranibizumab alone or in combination with laser photocoagulation vs. laser photocoagulation alone in proliferative diabetic retinopathy (PRIDE). Available from: https://clinicaltrials.gov/ct2/show/NCT01594281
   Google Scholar
• Preoperative intravitreal ranibizumab for persistent diabetic vitreous haemorrhage. Available from: https://clinicaltrials.gov/ct2/show/NCT01030770
   Google Scholar